S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NASDAQ:MGEN

Miragen Therapeutics Stock Forecast, Price & News

$21.78
+1.71 (+8.52 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.50
Now: $21.78
$22.00
50-Day Range
$16.36
MA: $19.01
$24.93
52-Week Range
$4.66
Now: $21.78
$34.05
Volume55,891 shs
Average Volume134,029 shs
Market Capitalization$85.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Miragen Therapeutics logo

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

711th out of 1,923 stocks

Medical Laboratories Industry

13th out of 39 stocks

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200
Employees45

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.46 million
Book Value$6.78 per share

Profitability

Net Income$-41,870,000.00
Net Margins-1,393.50%

Miscellaneous

Market Cap$85.12 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable
$21.78
+1.71 (+8.52 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

How has Miragen Therapeutics' stock been impacted by Coronavirus?

Miragen Therapeutics' stock was trading at $0.6119 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MGEN shares have increased by 3,459.4% and is now trading at $21.78.
View which stocks have been most impacted by COVID-19
.

Is Miragen Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Miragen Therapeutics stock.
View analyst ratings for Miragen Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Miragen Therapeutics?

Wall Street analysts have given Miragen Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Miragen Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Miragen Therapeutics' next earnings date?

Miragen Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Miragen Therapeutics
.

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics, Inc. (NASDAQ:MGEN) posted its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. Miragen Therapeutics had a negative trailing twelve-month return on equity of 141.66% and a negative net margin of 1,393.50%.
View Miragen Therapeutics' earnings history
.

What price target have analysts set for MGEN?

6 Wall Street analysts have issued 1-year target prices for Miragen Therapeutics' stock. Their forecasts range from $6.00 to $37.00. On average, they anticipate Miragen Therapeutics' share price to reach $16.33 in the next year. This suggests that the stock has a possible downside of 25.0%.
View analysts' price targets for Miragen Therapeutics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Miragen Therapeutics?

Miragen Therapeutics saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 161,700 shares, a decline of 14.2% from the December 15th total of 188,500 shares. Based on an average daily trading volume, of 446,900 shares, the days-to-cover ratio is presently 0.4 days. Currently, 4.4% of the shares of the company are sold short.
View Miragen Therapeutics' Short Interest
.

Who are some of Miragen Therapeutics' key competitors?

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Novan (NOVN) and Aeterna Zentaris (AEZS).

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the following people:
  • Mr. Jason A. Leverone CPA, CPA, CFO, Sec. & Treasurer (Age 46, Pay $355k)
  • Dr. William Stuart Marshall Ph.D., Co-Founder & Sr. Technical Advisor (Age 56, Pay $521k)
  • Dr. Diana Escolar, Chief Medical Officer (Age 58, Pay $484.38k)
  • Ms. Lee M. Rauch, CEO & Director (Age 65)
  • Dr. Jonathan Violin Ph.D., Pres & COO (Age 45)
  • Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 75)
  • Dr. Marvin H. Caruthers, Co-Founder & Scientific Advisory Board Member (Age 80)
  • Mr. Vahe Bedian Ph.D., Chief Scientific Officer
  • Dr. Aimee L. Jackson, VP of Research

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $21.78.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $85.12 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($20.09) on an earnings per share basis. Miragen Therapeutics employs 45 workers across the globe.

What is Miragen Therapeutics' official website?

The official website for Miragen Therapeutics is www.signalgenetics.com.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.